论文部分内容阅读
[目的]研究乳腺癌新辅助化疗后行前哨淋巴结活检(SLNB)的准确性、可行性。[方法]比较接受新辅助化疗的乳腺癌和未接受新辅助化疗乳腺癌SLNB的成功率、灵敏度、假阴性率、准确性,以及SLNB、腋窝淋巴结清扫(ALND)淋巴结检出枚数,同时对影响SLNB的因素进行讨论。[结果]26例新辅助化疗后乳腺癌SLNB的成功率、灵敏度、假阴性率、准确性分别为92.3%、90.9%、9.1%和95.8%,SLNB和ALND平均检出淋巴结分别为1.5、13.5枚,对比非新辅助化疗病例,均无明显统计学差异。肿瘤的位置、多灶性、前哨淋巴结的数量等可能是影响乳腺癌新辅助化疗后SLNB的因素。[结论]乳腺癌新辅助化疗后SLNB基本上是安全可行的。
[Objective] To study the accuracy and feasibility of sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy in breast cancer. [Methods] To compare the success rate, sensitivity, false negative rate, accuracy, and the number of SLNB and axillary lymph node dissection (ALND) lymph nodes in breast cancer patients receiving neoadjuvant chemotherapy and non-neoadjuvant chemotherapy breast cancer SLNB, SLNB factors are discussed. [Results] The success rate, sensitivity, false negative rate and accuracy of SLNB in breast cancer patients after neoadjuvant chemotherapy were 92.3%, 90.9%, 9.1% and 95.8%, respectively. The mean lymph node counts of SLNB and ALND were 1.5, 13.5 Pieces, compared with non-neoadjuvant chemotherapy cases, no significant statistical difference. The location of tumor, multifocality and the number of sentinel lymph nodes may be the factors affecting SLNB after neoadjuvant chemotherapy in breast cancer. [Conclusion] SLNB is basically safe and feasible after neoadjuvant chemotherapy for breast cancer.